Arrowhead Pharmaceuticals Inc (ARWR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arrowhead Pharmaceuticals Inc (ARWR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3456
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp, is a pharmaceutical company that develops and markets medicinal products. The company develops pipeline drugs that are being developed to treat chronic hepatitis B virus infection for the treatment of liver disease, thrombosis and angioedema, cardiovascular disease and clear cell and renal cell carcinoma, among others. It offers design of internal preclinical and clinical development programs to enable novel new therapies. Arrowhead develops pipeline products such as ARO-AAT, ARO-HBV, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, AMG 890 and ARO-AMG1. The company has operations in California and Wisconsin. Arrowhead is headquartered in Pasadena, California, the US.

Arrowhead Pharmaceuticals Inc (ARWR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arrowhead Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Arrowhead Research Acquires RNAi R&D Portfolio from Novartis for USD35 Million 13
Partnerships 15
Arrowhead Pharma Partners with Spring Bank Pharma 15
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 16
Licensing Agreements 17
Amgen Enters into Licensing Agreement with Arrowhead Pharma 17
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 18
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 19
Equity Offering 20
Arrowhead Pharma Raises USD60.4 Million in Public Offering of Shares 20
Arrowhead Pharma to Raise Funds through Public Offering of Shares 22
Arrowhead Pharma Raises USD45 Million in Private Placement of Shares 23
Arrowhead Research Completes Public Offering Of Shares For US$120 Million 25
Arrowhead Research Completes Private Placement Of Shares For US$18 Million 26
Arrowhead Research Completes Private Placement Of Preferred Shares For US$46 Million 28
Arrowhead Research Completes Private Placement Of Shares For US$26 Million 30
Arrowhead Research Completes Private Placement Of Preferred Shares For US$10 Million 32
Arrowhead Research Completes Public Offering Of Units For US$3.5 Million 34
Arrowhead Research Completes Public Offering Of Units For US$4.3 Million 35
Arrowhead Research Raises USD6.2 Million in Private Placement Of Units 36
Acquisition 37
Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 37
Arrowhead Research Acquires Alvos Therapeutics 38
Arrowhead Pharmaceuticals Inc – Key Competitors 39
Arrowhead Pharmaceuticals Inc – Key Employees 40
Arrowhead Pharmaceuticals Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
May 08, 2018: Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results 42
Feb 09, 2018: Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results 43
Dec 12, 2017: Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results 44
Feb 06, 2017: Arrowhead Reports Fiscal 2017 First Quarter Results 45
Corporate Communications 46
Dec 27, 2017: Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors 46
Clinical Trials 47
Oct 23, 2017: Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting 2017 47
Oct 10, 2017: Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting 48
Other Significant Developments 49
Aug 07, 2018: Arrowhead Pharmaceuticals reports fiscal 2018 third quarter results 49
May 03, 2017: Arrowhead Reports Fiscal 2017 Second Quarter Results 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arrowhead Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arrowhead Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Arrowhead Research Acquires RNAi R&D Portfolio from Novartis for USD35 Million 13
Arrowhead Pharma Partners with Spring Bank Pharma 15
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 16
Amgen Enters into Licensing Agreement with Arrowhead Pharma 17
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 18
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 19
Arrowhead Pharma Raises USD60.4 Million in Public Offering of Shares 20
Arrowhead Pharma to Raise Funds through Public Offering of Shares 22
Arrowhead Pharma Raises USD45 Million in Private Placement of Shares 23
Arrowhead Research Completes Public Offering Of Shares For US$120 Million 25
Arrowhead Research Completes Private Placement Of Shares For US$18 Million 26
Arrowhead Research Completes Private Placement Of Preferred Shares For US$46 Million 28
Arrowhead Research Completes Private Placement Of Shares For US$26 Million 30
Arrowhead Research Completes Private Placement Of Preferred Shares For US$10 Million 32
Arrowhead Research Completes Public Offering Of Units For US$3.5 Million 34
Arrowhead Research Completes Public Offering Of Units For US$4.3 Million 35
Arrowhead Research Raises USD6.2 Million in Private Placement Of Units 36
Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 37
Arrowhead Research Acquires Alvos Therapeutics 38
Arrowhead Pharmaceuticals Inc, Key Competitors 39
Arrowhead Pharmaceuticals Inc, Key Employees 40
Arrowhead Pharmaceuticals Inc, Other Locations 41
Arrowhead Pharmaceuticals Inc, Subsidiaries 41

List of Figures
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arrowhead Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arrowhead Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Arrowhead Pharmaceuticals Inc (ARWR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CHDI Foundation Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CHDI Foundation Inc (CHDI) is a non-profit biomedical research organization that discovers and develops drugs for Huntington’s disease. The organization’s activities include identification and validation of therapeutic targets, drug discovery and development, and clinical studies and trials. …
  • Consumers Energy Co (CMS PR B):石油・ガス:M&Aディール及び事業提携情報
    Summary Consumers Energy Co (Consumers), formerly Consumers Power, is an electric and natural gas utility. The company generates purchases, transmits, distributes, and sells electricity. It also carries out the purchase, transmission, storage, distribution, and sale of natural gas. It generates elec …
  • Elia System Operator SA (ELI):電力:M&Aディール及び事業提携情報
    Summary Elia System Operator SA (Elia) is a transmission system operator. It owns and operates high-voltage electricity transmission systems in Belgium and Germany. The company transmits electricity from generators to distribution system operators and industrial consumers. Elia also imports and expo …
  • gategroup Holding AG:企業の戦略・SWOT・財務分析
    gategroup Holding AG - Strategy, SWOT and Corporate Finance Report Summary gategroup Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • OdontoPrev SA (ODPV3):企業の財務・戦略的SWOT分析
    OdontoPrev SA (ODPV3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Roust Corporation:企業の戦略・SWOT・財務情報
    Roust Corporation - Strategy, SWOT and Corporate Finance Report Summary Roust Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Avisa Pharma Inc:医療機器:M&Aディール及び事業提携情報
    Summary Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections. The company provides product such as avisa breath test kit, which is designed to detect respiratory bacterial infections in the lung and other metabolic di …
  • Pt Indofood Sukses Makmur Tbk
    Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Damodar Valley Corp:企業の戦略的SWOT分析
    Damodar Valley Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Fitbit Inc.:戦略・SWOT・企業財務分析
    Fitbit Inc. - Strategy, SWOT and Corporate Finance Report Summary Fitbit Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Ashtead Group Plc (AHT):企業の財務・戦略的SWOT分析
    Ashtead Group Plc (AHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PPL Corp (PPL):石油・ガス:M&Aディール及び事業提携情報
    Summary PPL Corp (PPL) is an energy holding company. Through its subsidiaries, LG&E, Kentucky Utilities, and KU Energy, it generates, transmits, distributes, and sells electricity; and distributes and sells natural gas. The company produces electricity from coal, natural gas, oil, hydro, and solar s …
  • HCL Technologies Limited:企業の戦略・SWOT・財務分析
    HCL Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary HCL Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Dongfang Electric Corporation Ltd (1072)-エネルギー分野:企業M&A・提携分析
    Summary Dongfang Electric Corporation Ltd (DEC) a subsidiary of Dongfang Electric Corporation, is a power equipment and services company. It designs, manufactures, and sells power generation equipment, including turbines for hydro, thermal, and nuclear power generation, wind turbine generator sets, …
  • China Petroleum & Chemical Corp (600028):企業の財務・戦略的SWOT分析
    China Petroleum & Chemical Corp (600028) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Hemispherx Biopharma Inc (HEB):製薬・医療:M&Aディール及び事業提携情報
    Summary Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chro …
  • BeyondSpring Inc (BYSI):製薬・医療:M&Aディール及び事業提携情報
    Summary BeyondSpring Inc (BeyondSpring) is a clinical stage biopharmaceutical company focused on the development of immune-oncology cancer therapies. The company offers lead compound, Plinabulin, is derived from a natural compound which holds a number of biochemical activities and provides multiple …
  • TOWER Limited:企業の戦略・SWOT・財務分析
    TOWER Limited - Strategy, SWOT and Corporate Finance Report Summary TOWER Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Hong Kong Polytechnic University:製薬・医療:M&Aディール及び事業提携情報
    Summary Hong Kong Polytechnic University (HKPU) is an educational university that provides research, training and professional education services. The university offers undergraduate, postgraduate, and doctoral level programs; joint research, academic program collaboration, research programs, confer …
  • Kotra Industries Berhad (KOTRA):企業の財務・戦略的SWOT分析
    Kotra Industries Berhad (KOTRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆